How will we make drug selection and sequencing choices now that biosimilars, including ant-TNF agents, are available?

How will we make drug selection and sequencing choices now that biosimilars, including ant-TNF agents, are available?

How will we make drug selection and sequencing choices now that biosimilars, including ant-TNF agents, are available?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Joseph Markenson, MD

Joseph Markenson, MD

Department of Rheumatology
Department of Medicine
Hospital for Special Surgery, New York, NY
Attending Physician, Hospital for Special Surgery
Professor of Clinical Medicine, Weill Cornell Medical College